Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 405 publications
Robust CD4+ CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma.
Journal: Science translational medicine
Published: July 29, 2026
International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 22, 2026
Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma.
Journal: Future oncology (London, England)
Published: July 14, 2026
Will mezigdomide find its place in the T-cell redirecting treatment landscape for relapsed multiple myeloma?
Journal: Lancet (London, England)
Published: June 10, 2026
Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 20, 2026
Patterns and perceptions of supplement use among patients with plasma cell disorders.
Journal: Blood cancer journal
Published: May 06, 2026
Belantamab Mafodotin for Patients With Multiple Myeloma: Clinical Development and Practical Strategies for Dose Optimization and Toxicity Management.
Journal: Clinical lymphoma, myeloma & leukemia
Published: April 07, 2026
Breaking new ground with antibody-drug conjugates in myeloma.
Journal: Blood
Published: April 02, 2026
Comparative cost per responder analysis of ciltacabtagene autoleucel and real-world standard of care therapy in patients with lenalidomide-refractory multiple myeloma.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: February 24, 2026
Last Updated: 09/26/2026